SEARCH

SEARCH BY CITATION

References

  • Baer J. C., Freeman A. A., Newlands E. S., Watson A. J., Rafferty J. A. and Margison G. P. (1993) Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer 67, 12991302.
  • Barvaux V. A., Ranson M., Brown R., McElhinney R. S., McMurry T. B. and Margison G. P. (2004a) Dual repair modulation reverses temozolomide resistance in vitro. Mol. Cancer Ther. 3, 123127.
  • Barvaux V. A., Lorigan P., Ranson M., Gillum A. M., McElhinney R. S., McMurry T. B. and Margison G. P. (2004b) Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA-alkyltransferase. Mol. Cancer Ther. 3, 12151220.
  • Biswas T., Ramana C. V., Srinivasan G., Boldogh I., Hazra T. K., Chen Z., Tano K., Thompson E. B. and Mitra S. (1999) Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 18, 525532.
  • Bocangel D. B., Finkelstein S., Schold S. C., Bhakat K. K., Mitra S. and Kokkinakis D. M. (2002) Multifaceted resistance of gliomas to temozolomide. Clin. Cancer Res. 8, 27252734.
  • Brophy T. R. O., McCafferty J., Tyrer J. H. and Eadie M. J. (1983) Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur. J. Clin. Pharmacol. 24, 103108.
  • Bykov V. J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K. G. and Selivanova G. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282288.
  • Ceccotti S., Aquilina G., Macpherson P., Yamada M., Karran P. and Bignami M. (1996) Processing of O6-methylguanine by mismatch correction in human cell extracts. Curr. Biol. 6, 15281531.
  • Chan C. L., Wu Z., Eastman A. and Bresnick E. (1992) Irradiation-induced expression of O6-methylguanine-DNA methyltransferase in mammalian cells. Cancer Res. 52, 18041809.
  • Chang D. K., Ricciardiello L., Goel A., Chang C. L. and Boland C. R. (2000) Steady-state regulation of the human DNA mismatch repair system. J. Biol. Chem. 275, 18 42418 431.
  • Curtin N. J., Wang L. Z., Yiakouvaki A. et al. (2004) Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. 10, 881889.
  • Duckett D. R., Drummond J. T., Murchie A. I., Reardon J. T., Sancar A., Lilley D. M. and Modrich P. (1996) Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl Acad. Sci. USA 93, 64436447.
  • Esteller M., Garcia-Foncillas J., Andion E., Goodman S. N., Hidalgo O. F., Vanaclocha V., Baylin S. B. and Herman J. G. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 13501354.
  • Foster B. A., Coffey H. A., Morin M. J. and Rastinejad F. (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286, 25072510.
  • Friedman H. S., Pluda J., Quinn J. A. et al. (2000) Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 18, 35223528.
  • Friedman H. S., Keir S., Pegg A. E., Houghton P. J., Colvin O. M., Moschel R. C., Bigner D. D. and Dolan M. E. (2002) O6-benzylguanine-mediated enhancement of chemotherapy. Mol. Cancer Ther. 1, 943948.
  • Gerson S. L. (2002) Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20, 23882399.
  • Glaser T., Wagenknecht B. and Weller M. (2001) Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene 20, 47574767.
  • Glioma Meta-analysis Trialists Group (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 10111018.
  • Grombacher T., Mitra S. and Kaina B. (1996) Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of the base excision repair genes. Carcinogenesis 17, 23292336.
  • Grombacher T., Eichhorn U. and Kaina B. (1998) p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene 17, 845851.
  • Hammond L., Eckardt J. R., Baker S. D. et al. (1999) Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J. Clin. Oncol. 17, 26042613.
  • Harris L. C., Remack J. S., Houghton P. J. and Brent T. P. (1996) Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res. 56, 20292032.
  • Hegi M. E., Diserens A. C., Godard S. et al. (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10, 18711874.
  • Hegi M. E., Diserens A. C., Gorlia T. et al. (2005) MGMT gene silencing and response to temozolomide in glioblastoma. N. Engl. J. Med. 352, 9971003.
  • Hickman M. J. and Samson L. D. (1999) Role of DNA mismatch repair and p53 in signalling induction of apoptosis by alkylating agents. Proc. Natl Acad. Sci. USA 96, 10 76410 769.
  • Hickman M. J. and Samson L. D. (2004) Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. Mol. Cell 14, 105116.
  • Hirose Y., Berger M. S. and Pieper R. O. (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61, 19571963.
  • Kaina B. and Christmann M. (2002) DNA repair in resistance to alkylating anticancer drugs. Int. J. Clin. Pharm. Ther. 40, 354367.
  • Kaina B., Fritz G., Mitra S. and Coquerelle T. (1991) Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12, 18571867.
  • Kaina B., Mühlhausen U., Piee-Staffa A., Christmann M., Garcia Boy R., Rosch F. and Schirrmacher R. (2004) Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J. Pharmacol. Exp. Ther. 311, 585593.
  • Kanzawa T., Bedwell J., Kondo Y., Kondo S. and Germano I. M. (2003) Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J. Neurosurg. 99, 10471052.
  • Kokkinakis D. M., Bocangel D. B., Schold S. C., Moschel R. C. and Pegg A. E. (2001) Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin. Cancer Res. 7, 421428.
  • Ma J., Murphy M., O'Dwyer P. J., Berman E., Reed K. and Gallo J. M. (2002) Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem. Pharmacol. 63, 12191228.
  • Naumann U., Durka S. and Weller M. (1998) Dexamethasone-mediated protection from drug cytotoxicity: association with p21 WAF1/CIP1 protein accumulation? Oncogene 17, 15671575.
  • Ochs K. and Kaina B. (2000) Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 60, 58155824.
  • Pagani E., Pepponi R., Fuggetta M. P. et al. (2003) DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system. J. Chemother. 15, 173183.
  • Pegg A. E. (1990) Properties of mammalian O6-alkylguanine-DNA transferases. Mutat. Res. 233, 165175.
  • Pepponi R., Marra G., Fuggetta M. P., Falcinelli S., Pagani E., Bonmassar E., Jiricny J. and D'Atri S. (2003) The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J. Pharmacol. Exp. Ther. 304, 661668.
  • Preuss I., Eberhagen I., Haas S., Eibl R. H., Kaufmann M., Von Minckwitz G. and Kaina B. (1995) O6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int. J. Cancer 61, 321326.
  • Preuss I., Haas S., Eichhorn U. et al. (1996) Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue. Cancer Detect. Prev. 20, 130136.
  • Quinn J. A., Pluda J., Dolan M. E. et al. (2002) Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20, 22772283.
  • Rafferty J. A., Clarke A. R., Sellappan D., Koref M. S., Frayling I. M. and Margison G. P. (1996) Induction of murine O6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene 12, 693697.
  • Richter O., Ern B., Reinhardt D. and Becker B. (1983) Pharmacokinetics of dexamethasone in children. Ped. Pharmacol. 3, 329337.
  • Rohdewald P., Möllmann H., Barth J., Rehder J. and Derendorf H. (1987) Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm. Drug Dispos. 8, 205212.
  • Roos W., Baumgartner M. and Kaina B. (2004) Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 23, 359367.
  • Silber J. R., Bobola M. S., Ghatan S., Blank A., Kolstoe D. D. and Berger M. S. (1998) O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 58, 10681073.
  • Srivenugopal K. S., Shou J., Mullapudi R., Lang F. F., Rao J. S. and Ali-Osman F. (2001) Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin. Cancer Res. 7, 13981409.
  • Streffer J. R., Rimner A., Rieger J., Naumann U., Rodemann H. P. and Weller M. (2002) Bcl-2 family protein expression modulates radiosensitivity in human glioma cells. J. Neuro-Oncol. 56, 4349.
  • Stupp R., Mason W. P., Van Den Bent M. J. et al. on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) (2005) Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N. Engl. J. Med. 352, 987996.
  • Sur P., Sribnick E. A., Patel S. J., Ray S. K. and Banik N. L. (2005) Dexamethasone decreases temozolomide-induced apoptosis in human glioblastoma T98G cells. Glia 50, 160167.
  • Tentori L., Lacal P. M., Benincasa E., Franco D., Faraoni I., Bonmassar E. and Graziani G. (1998) Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J. Pharmacol. Exp. Ther. 285, 884893.
  • Tentori L., Portarena I., Bonmassar E. and Graziani G. (2001) Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly(ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ. 8, 457469.
  • Ueda S., Mineta T., Nakahara Y., Okamoto H., Shiraishi T. and Tabuchi K. (2004) Induction of the DNA repair gene O6-methylguanine-DNA-methyltransferase by dexamethasone in glioblastomas. J. Neurosurg. 101, 659663.
  • Wedge S. R. and Newlands E. S. (1996) O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br. J. Cancer 73, 10491052.
  • Weller M., Frei K., Groscurth P., Krammer P. H., Yonekawa Y. and Fontana A. (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J. Clin. Invest. 94, 954964.
  • Weller M., Schmidt C., Roth W. and Dichgans J. (1997) Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 48, 17041709.
  • Weller M., Rieger J., Grimmel C., Van Meir E. G., De Tribolet N., Krajewski S., Reed J. C., Von Deimling A. and Dichgans J. (1998) Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer 79, 640644.
  • Wick W., Wick A., Schulz J. B., Dichgans J., Rodemann H. P. and Weller M. (2002) Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res. 62, 19151919.
  • Wischhusen J., Naumann U., Ohgaki H., Rastinejad F. and Weller M. (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent cell death. Oncogene 22, 82338245.
  • Yung W. K., Prados M. D., Yaya-Tur R. et al. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 27622771.
  • Yung W. K., Albright R. E., Olson J. et al. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588593.